Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Talazoparib and AT13387 in Advanced Solid Tumors
NCT02627430Phase 1Withdrawn
- Sponsor
- National Cancer Institute
- Start
- Mar 2016
- Primary completion
- Mar 2019
- Modality
- Small Molecules
01
Overview
Phase 1, open-label, single-arm trial of talazoparib and onalespib in solid tumor (advanced stage), ovarian cancer, fallopian tube cancer (PFTC) and 2 more, sponsored by National Cancer Institute. Primary endpoint: Maximum Tolerated Dose at 35 days. Planned start Mar 2016; status: withdrawn.
02
Drugs
talazoparibonalespib
03
Conditions
solid tumor (advanced stage)ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT02627430.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02627430.